Non-dopaminergic treatments for motor control in Parkinson's disease (Q38126817)

29 August 2017

Non-dopaminergic treatments for motor control in Parkinson's disease (English)

1 reference

29 August 2017

1 reference

1 reference

1

Susan H Fox

1 reference

29 August 2017

1 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

73

1 reference

29 August 2017

13

1 reference

29 August 2017

1405-1415

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0105-4

29 August 2017

0 references

cites work

Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

The neuropathologic basis of different clinical subgroups of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Nondopaminergic mechanisms in levodopa-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Non-dopaminergic treatments in development for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Targeting adenosine A2A receptors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Metabotropic glutamate receptors in the basal ganglia motor circuit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Buspirone in the treatment of levodopa induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Placebo influences on dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Neural substrates linking balance control and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

History of falls in Parkinson disease is associated with reduced cholinergic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Primate models of movement disorders of basal ganglia origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3‐month observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Mirtazapine in Parkinsonian tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0105-4

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

21 January 2018

1 reference

12 December 2020

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

1 reference

12 December 2020

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

1 reference

12 December 2020

Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor

1 reference

12 December 2020

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

1 reference

12 December 2020

Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.

1 reference

12 December 2020

Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease

1 reference

12 December 2020

Beta-blocker therapy for tremor in Parkinson's disease

1 reference

12 December 2020

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

12 December 2020

A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease

1 reference

12 December 2020

Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia

1 reference

12 December 2020

Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease

1 reference

12 December 2020

Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor

1 reference

12 December 2020

Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys

1 reference

12 December 2020

The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients

1 reference

12 December 2020

Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?

1 reference

12 December 2020

Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

1 reference

12 December 2020

Drugs in development for Parkinson's disease.

1 reference

12 December 2020

10.1007/S40265-013-0105-4

Identifiers

DOI

1 reference

PubMed ID

23917951

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23917951